Viking Therapeutics to Participate in Fireside Chat at BTIG Biotechnology Conference 2022
Viking Therapeutics, Inc. (NASDAQ: VKTX) announced that CEO Brian Lian, Ph.D., will participate in a fireside chat at the BTIG Biotechnology Conference 2022 on August 8-9, 2022. The event will be a hybrid format, facilitating both in-person and virtual attendance. Viking focuses on developing innovative therapies for metabolic and endocrine disorders, including its clinical programs VK2809, VK2735, and VK0214. VK2809 is currently in a Phase 2b study for non-alcoholic steatohepatitis, showing promising results for lipid and metabolic disorders.
- None.
- None.
SAN DIEGO, Aug. 2, 2022 /PRNewswire/ -- Viking Therapeutics, Inc. ("Viking") (NASDAQ: VKTX), a clinical-stage biopharmaceutical company focused on the development of novel therapies for metabolic and endocrine disorders, today announced that its chief executive officer, Brian Lian, Ph.D., will participate in a fireside chat as part of the BTIG Biotechnology Conference 2022. The conference will take place August 8-9, 2022.
Details are as follows:
- BTIG Biotechnology Conference 2022
Details: Brian Lian, Ph.D., chief executive officer of Viking, will participate in a fireside chat and Viking management will participate in 1-on-1 meetings
Conference Dates: August 8-9, 2022
Format: Hybrid event with in-person and virtual participation
About Viking Therapeutics, Inc.
Viking Therapeutics is a clinical-stage biopharmaceutical company focused on the development of novel first-in-class or best-in-class therapies for the treatment of metabolic and endocrine disorders. Viking's research and development activities leverage its expertise in metabolism to develop innovative therapeutics designed to improve patients' lives. The company's clinical programs include VK2809, a novel, orally available, small molecule selective thyroid hormone receptor beta agonist for the treatment of lipid and metabolic disorders, which is currently being evaluated in a Phase 2b study for the treatment of biopsy-confirmed non-alcoholic steatohepatitis (NASH) and fibrosis. In a Phase 2a trial for the treatment of non-alcoholic fatty liver disease (NAFLD) and elevated LDL-C, patients who received VK2809 demonstrated statistically significant reductions in LDL-C and liver fat content compared with patients who received placebo. The company is also developing VK2735, a novel dual agonist of the glucagon-like peptide 1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP) receptors for the potential treatment of various metabolic disorders. VK2735 is currently being evaluated in a Phase 1 clinical trial. The company's third clinical compound is VK0214, a novel, orally available, small molecule selective thyroid hormone receptor beta agonist for the potential treatment of X-linked adrenoleukodystrophy (X-ALD). VK0214 is currently being evaluated in a Phase 1b clinical trial in patients with the adrenomyeloneuropathy (AMN) form of X-ALD. The company holds exclusive worldwide rights to a portfolio of five therapeutic programs, including VK2809 and VK0214, which are based on small molecules licensed from Ligand Pharmaceuticals Incorporated.
For more information about Viking Therapeutics, please visit www.vikingtherapeutics.com. Follow Viking on Twitter @Viking_VKTX.
View original content to download multimedia:https://www.prnewswire.com/news-releases/viking-therapeutics-to-participate-in-fireside-chat-at-btig-biotechnology-conference-2022-301598185.html
SOURCE Viking Therapeutics, Inc.
FAQ
What is the date of the BTIG Biotechnology Conference 2022?
Who will represent Viking Therapeutics at the BTIG conference?
What is VKTX currently working on in clinical trials?
What therapeutic areas does Viking Therapeutics focus on?
What are the main clinical programs of Viking Therapeutics?
